103 results about "Malaria" patented technology

Methods of treating malaria comprising administration of compounds of Formula (I′) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. It also provides uses of the compounds of Formula (I), as defined herein, for inhibiting plasmepsin X, plasmepsin IX or plasmepsin X and IX activity, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

Provided are methods for treatment of pathological conditions causing hemolysis, cerebral edema, acute kidney injury and non-anaphylactic shock, including envenomation, trauma, cerebral malaria and mast-cell diseases using at least one PLA2 inhibitor, alone or in combination with other agents. The unexpected versatility of PLA2 inhibitors, their dosage forms and combinations make them candidates as essential medicines for the developing world.

Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.

The present invention is related to new compounds useful in the manufacture of a medicament for preventing or treating malaria, pharmaceutical compositions, methods of preparation and uses thereof.

The utility model discloses a portable multifunctional malaria diagnosis and treatment tool box which comprises a box body and a box cover, a storage space is formed in the box body, and the box cover is rotationally connected with the box body; the partition plate is arranged in the box body, at least two positioning rods are arranged in vertical through grooves in the left side wall and the right side wall of the storage space, the positioning rods and the side wall of the partition plate are oppositely arranged, and positioning holes are formed in the positioning rods; the at least two barrier plates are arranged between the side wall of the partition plate and the positioning rod; the blocking column is arranged on the blocking plate; the transverse through hole is formed in the side wall of the storage space and is communicated with the vertical through groove; when the positioning rod moves to the first position, the blocking columns make contact with a rod body of the positioning rod, the partition plates are clamped between the blocking plates, the positions of the partition plates are fixed, the partition plates cannot move along with shaking of the tool box, and the probability that articles in the storage space fall off and shake is effectively reduced; when the positioning rod moves to the second position, the blocking column is arranged in the positioning hole, and a gap is formed between the blocking plate and the partition plate, so that the partition plate can be conveniently moved to change the size of the storage space, the device is portable and multipurpose, and the diagnosis and treatment requirements of malaria in outdated and remote areas are met.

The present invention relates to pharmaceutical preparations containing as active ingredients 3-N-formylhydroxylaminopropylphosphonic acid derivatives or 3-N-acetylhydroxylaminopropylphosphonic acid derivatives in combination with clindamycin and artesunate for the treatment of malaria, in particular for the acute therapy of cerebral malaria, and to an associated dosage, in particular for the patient group of children.

The present disclosure provides anti-circumsporozoite (CSP) antibodies, compositions containing such antibodies, methods for producing the disclosed antibodies, and methods for using them to treat or prevent malaria, as well as methods for selecting antibodies as anti-malaria therapeutic antibodies.

This invention provides compounds for the treatment, prevention, or suppression of various pathological conditions (such as proliferative disorders like cancer, β-globin disorders, fibrosis, pain, neurodegenerative diseases, Prader-Willi syndrome, malaria, viral infections, myopathy, and autism) by inhibiting G9a. [Solution] The following general formula (I) TIFF2026062914000401.tif2449 A compound represented by or a pharmacoposly acceptable salt thereof is provided.

The present disclosure provides compositions (e.g., pharmaceutical compositions) and related techniques (e.g., components thereof and / or methods related thereto) for delivery of malaria protein antigens. The present disclosure provides, among other things, polyribonucleotides encoding malaria protein antigens.

According to the purposes of the present disclosure, as embodied and broadly described herein, the present disclosure relates, in one aspect, to scaffold molecules that exhibit potent anti-malarial activity against a variety of Plasmodium strains at different stages of a parasite, such as the red and infrared stages, and pharmaceutical compositions comprising the scaffold molecules. In one aspect, these compounds are tetrahydroacridones having Structure I described herein. In another aspect, the compounds described herein may be used to treat or prevent malaria in a subject.

Compounds of formula (I) or their pharmaceutically acceptable salts, hydrates, solvates, esters or their optical isomers, racemates, diastereoisomers, enantiomers, tautomers, or a mixture thereof; said compounds exhibits anti-plasmidal activities, in particular for the treatment of malaria diseases.

The present disclosure provides anti-circumsporozoite (CSP) antibodies, compositions comprising such antibodies. Also disclosed are methods of producing the disclosed antibodies and methods of treating or preventing malaria using the same.

A method for the treatment of malaria which comprises applying microwave energy to a patient under non-thermal conditions. The non-thermal conditions are achieved by applying the microwave energy under conditions that the normal heating effects of microwaves are not significant. For example, microwave energy may be switched on in pulses lasting less than 6 seconds.

Subject matter of the present invention is an angiotensin-receptor-agonist and / or a precursor thereof for use in the treatment of a disease in a subject, • wherein said disease is selected from the group comprising heart failure, chronic heart failure, acute heart failure (AHF), myocardial infarction (MI), stroke, liver failure, burn injuries, traumatic injuries, severe infection (microbial, viral (e.g. AIDS), parasitic diseases (e.g. Malaria)), SIRS or sepsis, cancer, acute kidney injury (AKI), CNS disorders (e.g. seizures, neurodegenerative diseases), autoimmune diseases, vascular diseases, hypotension and shock, and • wherein said subject has an amount of DPP3 protein and / or DPP3 activity in a sample of bodily fluid that is above a predetermined threshold.

A combination of a carrier sheet (6) and a mosquito net (1), wherein the mosquito net (1) comprises a mesh fabric (5) formed as a canopy to cover a bedding area and protect humans from insects, the carrier sheet (6) is made of a flexible material and has edges attached to the mesh fabric (5) optionally by sewing, and the carrier sheet (6) is loaded with a functional item for medical diagnosis, such as a malaria test kit.

The present invention discloses an artemisinin PROTACs, a preparation method and application thereof, wherein the structural formula is: The present invention uses artemisinin modified product artesunate as POI ligand, lenalidomide and pomalidomide as E3 ligands, and linkers selected from amino acid chains, PEG chains and fatty chains. The anticancer activity thereof is superior to that of artesunate, and the present invention has good potential application prospects in anticancer drugs and treatment of critical malaria.

The utility model relates to the technical field of medical detection, in particular to a malaria colloidal gold kit capable of improving rapid detection efficiency, which comprises a kit body and a blood taking needle, the side wall of the kit body is provided with two notches, and the inner side of the kit body is fixedly provided with detection test paper; a clamping structure is mounted on the kit body and comprises a rotating shaft I rotationally connected to the side wall of the kit body. The blood taking needle is clamped and fixed through the clamping structure, so that the kit body is provided with the disposable blood taking needle in a matched mode, the disposable blood taking needle does not need to be cleaned after being used, the detection speed is greatly increased, dropped blood and buffering agents can be stirred through the stirring structure, and the detection accuracy is improved. Therefore, the mixing of the blood and the buffering agent is promoted.

The present application provides a compound of Formula (I): [Formula I] or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4, R5, R6, W, L, R8, and R9 are as described herein. Pharmaceutical compositions including these compounds and methods of using these compounds for treating parasitic infections (e.g., malaria), cancer, cardiovascular diseases, neurological diseases, inflammatory diseases, neuropathic pain, and other conditions are also disclosed herein.

The invention discloses a novel Kdo-MPLA adjuvant, and relates to the technical field of synthetic biology, the adjuvant is formed by connecting monophosphate lipid A (MPLA) and Kdo sugar through an alpha-glucosidic bond, MPLA is of a structure formed by modifying salmonella lipid A through 4 '-site monophosphorylation, and the Kdo sugar is endowed with amphipathy, so that the Kdo sugar is self-assembled into liposome nanoparticles in an aqueous solution; the rfaC and eptA genes are double knocked out through a gene editing salmonella attenuated strain, wherein the rfaC knockout blocks the synthesis of LPS core polysaccharide, and lipid A-Kdo connection is reserved; knocking out eptA to obtain a monophosphorylated lipid A; after the engineering bacteria are fermented, high-purity Kdo-MPLA is obtained by adopting a phenol-chloroform-petroleum ether extraction method, the process is simplified, and the product is uniform; the adjuvant can activate a TLR4 signal channel and induce Th1 type immune response, the levels of inflammatory factors IL-6 and IL-1beta are remarkably lower than those of natural LPS, and the adjuvant is suitable for a mixed preparation of vaccine antigens such as HPV and malaria; the method overcomes the defects of hydrolysis uncontrollability and high chemical synthesis cost of the traditional MPLA chemical extraction process.

Disclosed is a use of artemether in preventing and treating Alzheimer's disease. Artemether is a safe and effective compound for treatment against malaria. Artemether activates an AMPK signaling pathway in the brain of a transgenic mouse model of Alzheimer's disease, improves learning and memory abilities in the mouse model, reduces neuron apoptosis in the brain, improves function of choline acetyltransferase, inhibits activity of glial cells, and reduces amyloid plaque deposition, neurofibrillary tangle, and neuron loss, thereby providing an experimental basis for clinical research on the treatment of Alzheimer's disease.

The present application relates to a preparation of a 7,7'-epoxy lignan compound and its application in preparing anti-malaria products, and belongs to the field of traditional Chinese medicine and natural medicine pharmacy. The anti-malaria medicine with the compound as an active ingredient. The present application expands the medicinal value of 7,7'-epoxy lignan compounds in Rhodiola henryi.

The present disclosure provides nanostructures and nanostructure-based vaccines. Some nanostructures of the present disclosure display antigens capable of eliciting an immune response to infectious agents such as bacteria, viruses, and pathogens. Some vaccines of the present disclosure are useful for preventing or reducing the severity of infection by infectious agents including, but not limited to, Lyme disease, pertussis, herpes virus, orthomyxovirus, paramyxovirus, pneumovirus, filovirus, flavivirus, reovirus, retrovirus, meningococcus, or malaria. The antigens can be attached to the core of the nanostructure non-covalently or covalently, including as a fusion protein or by other means disclosed herein. Multimeric antigens can optionally be displayed along the symmetry axis of the nanostructure. Also provided are proteins and nucleic acid molecules encoding such proteins, vaccine compositions, and methods of administration.

Disclosed herein are methods and compositions for treating a disease or disorder in a subject in need thereof. The methods may include administering to the subject a therapeutically effective amount of a GPR37 agonist. The disease or disorder may be selected from inflammation, inflammatory pain, chronic pain, viral infection, bacterial infection, malaria, sepsis, or a combination thereof.

The invention relates to the substances benfo-oxythiamine (B-OT) and / or oxythiamine (OT) as an active ingredient of a medicament, in particular a human medicament, for the therapeutic treatment of infections with sporozoa of the genus Plasmodium and malaria disease caused thereby in a patient or potential patient.

This invention relates to antibodies for the treatment or prevention of malaria.

Disclosed herein are new salts and polymorphs of cethromycin for the treatment of diseases due to infection by bacteria and certain protozoans, including, for example, malaria, Babesosis, Toxoplasmosis, diarrheal disease, respiratory disease, sexually transmitted bacterial infections, and some bioterror bacteria, including, for example, plague, tularemia and post-inhalation anthrax. Also disclosed herein are new salts and polymorphs of cethromycin for the treatment of inflammatory diseases, including, for example, pelvic inflammatory disease, and peptic ulcer disease.

Representatives of 3-(acetylamidomethyl)phenylboronic acid derivatives with general Formula I show potency to inhibit malarial subtilisin-like serine protease (SUB) in low micromolar to nanomolar concentrations. As such they can be applied as compounds for prevention or treatment of malaria. (I)

The invention discloses a malaria pathogen detection system based on an improved YOLO algorithm. The malaria pathogen detection system comprises a blood sampling module, a microfluidic processing module, a microscopic imaging module, an AI analysis module and a display screen, the blood sampling module is used for quickly collecting a blood sample from a fingertip; the microfluidic processing module is used for integrating a thin film heater and accurately controlling the temperature of a sample; the microscopic imaging module is used for integrating a Raspberry Pi HQ Camera module and an automatic focusing motor MEMS (Micro Electro Mechanical System) micromirror, and converting a blood sample into a digital image through a high-precision lens and a dynamic focusing function; the AI analysis module is used for internally arranging an improved lightweight YOLO algorithm and carrying out efficient image processing and real-time pathogen detection in the equipment; and the display screen is used for outputting a real-time detection result and confidence in a two-stage display mode by using an OLED (Organic Light Emitting Diode) screen. According to the invention, the accuracy of disease detection is obviously improved.

This disclosure relates to a compound represented by formula I:(I) and a method for treating malaria parasitic infection, the method comprising administering the compound represented by formula I or a pharmaceutically acceptable salt thereof to a person in need of such treatment. [Formula 1] TIFF2026520957000151.tif23115